JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

B2293 Irinotecan HCl Trihydrate

Target: Topoisomerases

Summary: Topoisomerase 1 inhibitor

≥23.1 mg/mL
B2295 Pirarubicin
1 Citation

Target: Topoisomerases

Summary: Topoisomerase II inhibitor;anthracycline antibiotic

insoluble in H2O; insoluble in EtOH; ≥7.65 mg/mL
B4745 (S)-10-Hydroxycamptothecin

Target: Topoisomerases

Summary: inhibitor of topoisomerase I

≥23.8 mg/mL
B7382 Ellipticine

Target: Topoisomerases

Summary: DNA topoisomerase II inhibitor

≥24.6 mg/mL
B2290 Beta-Lapachone

Target: Topoisomerases

Summary: DNA topoisomerase I inhibitor,selective

insoluble in H2O; ≥10.85 mg/mL
A1832 Doxorubicin (Adriamycin) HCl
2 Citation

Target: Topoisomerases

Summary: Antitumour antibiotic,inhibits TOPO II.

≥29 mg/mL
A2877 Camptothecin
1 Citation

Target: Topoisomerases

Summary: Topoisomerase I inhibitor,prototypic

insoluble in H2O; insoluble in EtOH; ≥8.7 mg/mL
A1971 Etoposide
4 Citation

Target: Topoisomerases

Summary: Topo II inhibitor

≥112.6 mg/mL
A2451 Epirubicin HCl

Target: Topoisomerases

Summary: Antibiotic antitumor agent

≥29.00 mg/mL